China Pharmaceutical University Researchers Have Provided New Data on Pharmaceutical Research (Increasing the tumour targeting of antitumour drugs through anlotinib-mediated modulation of the extracellular matrix and the RhoA/ROCK signalling...).

Researchers from China Pharmaceutical University have conducted a study on the use of anlotinib, a drug with antiangiogenic effects, in combination with other antitumour drugs. Through their research, they discovered that anlotinib regulates the expression of components of the extracellular matrix (ECM), leading to a reduction in ECM stiffness. This, in turn, increases the distribution and retention of antitumour drugs in tumours. The study also found that anlotinib effectively suppresses the RhoA/ROCK signalling pathway. These findings contribute to the development of combination therapies aimed at improving tumour targeting in cancer treatment. [Extracted from the article]